Key Highlights
- Humacyte (NASDAQ:HUMA) fell 5.83% to USD 0.56 on November 13, 2026, with a Market Value of about USD 158 million and a 52-week range of USD 0.34 to USD 1.53.
- Third-quarter 2026 Symvess product Revenue was USD 1.02 million, up 151% from the second quarter and about 45% from a year earlier, and October sales alone reached USD 0.8 million.
- The net loss narrowed to USD 15.5 million, or USD 0.06 per share, from USD 17.5 million, and quarterly operating cash use fell to USD 15.0 million from USD 23.9 million.
- Cash, equivalents and restricted cash were USD 64.9 million at September 30, and the company plans to file a supplemental application for dialysis access in November 2026.
Early Commercial Traction
Humacyte (NASDAQ:HUMA) makes Symvess, a bioengineered human blood vessel approved for repairing vascular trauma. Sales remain small but are accelerating. The number of hospitals ordering rose to 49 from 34 in the second quarter, and management expects fourth-quarter sales to be at least double the third quarter, implying at least about USD 2 million, while targeting at least 20 new hospitals in the second half of 2026. October sales of USD 0.8 million suggest the guidance is achievable. The screen's 63.03% change in Earnings Per Share reflects a smaller loss per share, helped by a larger share count and lower spending, rather than profitability. Research costs fell to USD 14.1 million from USD 17.3 million, while general and administrative costs rose to USD 9.0 million from USD 7.6 million as the sales effort expanded. The nine-month net loss of USD 70.0 million was inflated by a non-cash change in the value of an earnout liability. Trauma surgeons have tended to adopt new products gradually, which makes hospital value committee approvals a useful leading indicator of future sales.
The Cash Question
Liquidity is the issue that keeps the stock below USD 1. Cash of USD 64.9 million compares with quarterly operating cash use of USD 15.0 million, which implies a little more than four quarters of funding at the current rate before other obligations, on our estimate. The Balance Sheet also carries USD 36.8 million of long-term debt, a non-current finance Lease of USD 29.1 million and a litigation settlement Liability of USD 9.75 million, against stockholders' Equity of only USD 18.1 million. The company has not stated a runway in its release. That leaves investors expecting new Capital within the next year, through equity sales, partnerships or Royalty financing, any of which could dilute holders at today's low price. A share price below USD 1 also raises the risk of an exchange compliance notice.
Pipeline Catalysts to Watch
The next driver is dialysis access. Humacyte plans to file a supplemental application in November 2026 to expand the use of its vessel to patients who need access for dialysis, based on two Phase 3 studies. Dialysis access is a much larger market than trauma repair, so approval would broaden the commercial case. A Phase 2a study in coronary bypass surgery, using a smaller-diameter vessel, activated its first site in November. For Humacyte (NASDAQ:HUMA), the near-term watch list is the dialysis filing and its acceptance, fourth-quarter Symvess sales against the doubling target, the number of hospitals ordering and any financing announcement. Faster sales growth would reduce dilution risk, while delays would increase it. Data presented at major vascular meetings will also shape how quickly surgeons try the product in new settings.
Where Things Stand
Humacyte (NASDAQ:HUMA) more than doubled Symvess sales from the second quarter and narrowed its loss, but quarterly sales of about USD 1 million are small against cash use of USD 15.0 million. Cash of USD 64.9 million funds roughly a year. The dialysis filing and any financing are the next events.






Please wait processing your request...